Free Trial
NASDAQ:ICLR

Icon Q2 2025 Earnings Report

Icon logo
$143.54 -3.34 (-2.27%)
Closing price 04:00 PM Eastern
Extended Trading
$140.00 -3.54 (-2.47%)
As of 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Icon EPS Results

Actual EPS
N/A
Consensus EPS
$3.18
Beat/Miss
N/A
One Year Ago EPS
N/A

Icon Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.98 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Icon Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, July 24, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Icon Earnings Headlines

Miss This Window And You Miss Everything
There’s a moment in every crypto cycle when everything just clicks — and that moment is now. This is the phase when momentum builds, news turns bullish, and markets ignite. Inside The Crypto Code Workshop, you’ll get the roadmap to ride this wave — and $10 in free Bitcoin just for showing up.
What is Leerink Partnrs' Estimate for Icon FY2025 Earnings?
See More Icon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Icon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Icon and other key companies, straight to your email.

About Icon

Icon (NASDAQ:ICLR) is a global contract research organization (CRO) specializing in the delivery of comprehensive drug development solutions to the pharmaceutical, biotechnology and medical device industries. Founded in 1990 and headquartered in Dublin, Ireland, the company provides a broad suite of services spanning clinical trial design, execution and management. By integrating scientific expertise with advanced data analytics and technology platforms, ICON supports its clients in bringing new therapies and medical products to market efficiently and in compliance with regulatory standards.

The company’s core offerings include clinical development services such as protocol design, patient recruitment and site management, safety and pharmacovigilance, biostatistics and data management. ICON also delivers specialized consulting solutions covering regulatory strategy, market access and health economics. Additionally, its real-world evidence and outcomes research capabilities draw on extensive patient data to inform product development decisions and optimize commercial strategies.

ICON operates in more than 50 countries with a network of regional offices across North America, Europe, Asia Pacific and Latin America. This global footprint enables the company to manage multi-site, multinational studies and to engage diverse patient populations. Over the years, ICON has expanded its reach and service portfolio through strategic acquisitions, most notably the integration of PRA Health Sciences in 2021, bolstering its capacity in late-stage clinical development and operational scale.

Originally established by John Climax, ICON has grown into one of the leading independent CROs under the leadership of Chief Executive Officer Peter Gray. The company’s senior management team combines deep industry experience with a commitment to innovation, quality and patient safety. As a publicly traded entity on the NASDAQ under the symbol ICLR, ICON remains focused on advancing clinical research through a client-centric approach and cutting-edge technological solutions.

View Icon Profile

More Earnings Resources from MarketBeat